|
Hemato-oncology
Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm
Ik-Chan Song, Sang Hoon Yeon, Myung-Won Lee, Hyewon Ryu, Hyo-Jin Lee, Hwan-Jung Yun, Seon Young Kim, Deog-Yeon Jo
Korean J Intern Med. 2021;36(5):1190-1203. Published online July 22, 2021
Background/Aims: Recent changes in the diagnostic criteria for myeloproliferative neoplasms (MPNs) and increasing patient numbers necessitate updating of the data on vascular events in patients with such disorders.
Methods: In this single-center study, thrombotic and hemorrhagic events were retrosp..
|
|
|
The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
Sung-Yong Kim, Sung Hwa Bae, Soo-Mee Bang, Ki-Seong Eom, Junshik Hong, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Min Kyoung Kim, Soo-Jeong Kim, Yeung-Chul Mun, Seung-Hyun Nam, Jinny Park, Jong-Ho Won, Chul Won Choi
Korean J Intern Med. 2021;36(1):45-62. Published online December 4, 2020
In 2016, the World Health Organization revised the diagnostic criteria for myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of patients with MPNs. Recent studies have suggested that additional som..
|
|
|
Recent insights regarding the molecular basis of myeloproliferative neoplasms
Mi-Ae Jang, Chul Won Choi
Korean J Intern Med. 2020;35(1):1-11. Published online November 29, 2019
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of clonal disorders characterized by the overproduction of mature blood cells that have an increased risk of thrombosis and progression to acute myeloid leukemia. Next-generation sequencing studies have provided key insights regarding the..
|
|
|
Hemato-oncology
Guidelines for the management of myeloproliferative neoplasms
Chul Won Choi, Soo-Mee Bang, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Soo-Jeong Kim, Yeo-Kyeoung Kim, Jinny Park, Jong-Ho Won
Korean J Intern Med. 2015;30(6):771-788. Published online October 30, 2015
Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as ‘Philadelphia-negative classical myeloproliferative neoplasms (MPNs).’ The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysio..
|
|
|
Diagnostic Usefulness of the Janus Kinase 2 Mutation in non BCR/ABL Myeloproliferative Disorders
Soo-Mee Bang, Jeong Yeal Ahn, Jiyoon Park, Soo Jin Yoo, Se Hoon Park, Eun Mi Nam, Pil Whan Park, Yiel Hea Seo, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
Korean J Intern Med. 2006;21(4):219-224. Published online December 31, 2006
BackgroundWe investigated the Janus kinase 2 (JAK2) mutation and its diagnostic value in patients suffering with non BCR/ABL myeloproliferative diseases (nMPD) or other reactive conditions. Methods..
|
|
|
